Wednesday, September 28, 2022
HomeInvestmentNirvana Appoints New Chief Monetary Officer

Nirvana Appoints New Chief Monetary Officer


Optimi Well being Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Firm”), a Canadian-based firm licensed by Well being Canada to provide pure, scalable, and accessible psychedelic and practical mushrooms, in addition to artificial formulations for transformational human experiences, is celebrating the launch of Blue Serenity, Canada’s first pure therapeutic psilocybin product, in collaboration with psilocybin affected person advocate Thomas Hartle.

Blue Serenity is standardized to comprise a complete of 25 milligrams of pure psilocybin within the type of EU-GMP biomass grown as Panaeolus cyanescens mushrooms cultivated at Optimi Labs Inc. in Princeton, British Columbia. Optimi’s Chief Science Officer, Justin Kirkland, and Head of Cultivation, Todd Henderson, collaborated with Hartle to breed a selected genetic pressure primarily based on Hartle’s earlier therapeutic experiences.

As soon as accepted by well being authorities beneath Canada’s Particular Entry Program (SAP) or a licensed medical trial, sufferers, docs, and researchers will obtain Blue Serenity in blister packs of eight (8) psilocybin capsules. Blue Serenity is packaged in response to present laws and pointers governing the manufacture and industrial distribution of medical/pharmaceutical merchandise (EU-GMP).

Optimi CEO, Invoice Ciprick, says the launch of Blue Serenity is a second to pause and replicate on Thomas’s monumental contributions to a world past psychedelics.

“Anybody who has entered the psychedelics house within the final two years will inform you that Thomas Hartle’s story of compassion and kindness impressed them indirectly to need to make a distinction,” stated Ciprick. “We’re tremendously excited to be partnering with Thomas to develop into the primary Canadian firm to launch a pure psilocybin product particularly to assist sufferers looking for reduction via the Particular Entry Program,” he added.

Additional, Ciprick confirmed that proceeds from the sale of Blue Serenity will instantly profit psilocybin sufferers via Hartle’s new charity, a enterprise that can present entry to psilocybin remedy for underserved adults. Optimi may even make a $5,000 financial donation to the charity in commemoration of the two-year anniversary of Mr. Hartle’s Well being Canada approval to endure psilocybin-assisted remedy.

“It is a wonderful alternative for Optimi to present again to these in want, whereas serving to to construct a community of belief between enterprise, advocacy, sufferers, and docs, that we hope will additional the framework for compliant entry and enhance the general confidence of practitioners on this medication,” Ciprick added.

Hartle’s alternative of the identify “Blue Serenity” touches on the emotional and visible facet of his psilocybin expertise, particularly in how he was capable of redefine the interior sense of peace his remedy introduced him.

“Blue Serenity was born from an expertise that took me from a state of maximum anxiousness to a sense of calm that I by no means knew existed,” stated Hartle. “Figuring out that my journey will stay on in a pure substance that others will be capable of entry goes to the core of every little thing that’s proper about psychedelic remedy, and that in itself is an extremely shifting expertise for me,” added Hartle.

Analysis reveals that as much as 80 p.c of sufferers with superior most cancers are prone to endure distressing ideas round loss of life and as much as 50 p.c of sufferers with usually incurable circumstances are prone to have psychiatric diagnoses.

Blue Serenity can be obtainable upon request to all authorized psilocybin sufferers whose entry has been accepted by Well being Canada beneath authorized mechanisms such because the SAP and Part 56 Exemptions to the Managed Medication and Substances Act, in addition to licensed researchers enthusiastic about standardized dosages of pure psilocybin.

Optimi Well being can be internet hosting a press convention with Thomas Hartle at 1:00 PM EST at the moment (Wednesday, August tenth, 2022) to offer extra particulars on the launch of Blue Serenity.

To entry at the moment’s 1:00 PM EST press convention, please click on right here .

For extra particulars or to request an interview, please contact:

Michael Kydd
michael@kyddergroup.com
902.880.6121

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Well being Corp. is a Canadian-based firm licensed by Well being Canada to provide and provide pure, EU-GMP grade psilocybin and artificial psychedelic substances, in addition to practical mushrooms that target the well being and wellness markets. Constructed with the aim of manufacturing scalable psychedelic formulations for transformational human experiences, the Firm’s objective is to be the primary trusted, compassionate provider of secure drug merchandise all through the world. Optimi’s merchandise are grown at its two services comprising a complete of 20,000 sq. toes in Princeton, British Columbia, making it the biggest psilocybin cultivator in North America.

ABOUT THOMAS HARTLE

Thomas Hartle is a 54-year-old husband, father, and IT skilled who was identified with stage 4 colon most cancers in 2016. Confronted with the everyday consequence of stage 4 most cancers, Thomas skilled a debilitating stage of hysteria over his future, in addition to that of his household. This anxiousness prompted him to discover new potential choices for his treatment-resistant situation. In August of 2020, Thomas turned the primary Canadian to legally obtain psilocybin-assisted psychotherapy.

Since that point, Thomas has skilled a considerable enchancment in each his emotional wellbeing and his total means to as soon as once more benefit from the time he has along with his household. He’s presently advocating using this remedy whereas present process his common most cancers therapy regime.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
E-mail: buyers@optimihealth.ca
Cellphone: +1 (902) 880 6121
Net: www.optimihealth.ca

FORWARD‐LOOKING STATEMENTS

This information launch comprises ahead‐trying statements and ahead‐trying info throughout the that means of Canadian securities laws (collectively, “ahead‐trying statements”) that relate to Optimi’s present expectations and views of future occasions. Any statements that specific, or contain discussions as to, expectations, beliefs, plans, targets, assumptions or future occasions or efficiency (typically, however not at all times, via using phrases or phrases equivalent to “will doubtless end result,” “are anticipated to,” “expects,” “will proceed,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “technique,” “goal,” and “outlook”) are usually not historic info and could also be ahead‐trying statements and should contain estimates, assumptions and uncertainties which may trigger precise outcomes or outcomes to vary materially from these expressed in such ahead‐trying statements. No assurance may be on condition that these expectations will show to be appropriate and such ahead‐trying statements included on this information launch shouldn’t be unduly relied upon. These statements converse solely as of the date of this information launch. Particularly and with out limitation, this information launch comprises ahead‐ trying statements pertaining to actions proposed to be carried out beneath the Firm’s vendor’s license and related enterprise associated to Psilocybin and Psilocin and Optimi’s plans, focus and targets.

Ahead‐trying statements are primarily based on a variety of assumptions and are topic to a variety of dangers and uncertainties, lots of that are past Optimi’s management, which may trigger precise outcomes and occasions to vary materially from these which are disclosed in or implied by such ahead‐trying statements. Such dangers and uncertainties embody, however are usually not restricted to, the influence and development of the COVID‐19 pandemic and different components set forth beneath “Ahead‐Trying Statements” and “Danger Components” within the Firm’s Annual info Type dated January 12, 2022, and different steady disclosure filings obtainable beneath Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to replace or revise any ahead‐trying statements, whether or not because of new info, future occasions or in any other case, besides as could also be required by regulation. New components emerge every now and then, and it’s not potential for Optimi to foretell all of them or assess the influence of every such issue or the extent to which any issue, or mixture of things, might trigger outcomes to vary materially from these contained in any ahead‐trying assertion.

Any ahead‐trying statements contained on this information launch are expressly certified of their entirety by this cautionary assertion.

Photographs accompanying this announcement can be found at

https://www.globenewswire.com/NewsRoom/AttachmentNg/a37f9f1c-c100-4e5b-a133-e1494ba7148c

https://www.globenewswire.com/NewsRoom/AttachmentNg/7ea1098e-ebbc-4ca7-98f0-67c7ca97fef8
https://www.globenewswire.com/NewsRoom/AttachmentNg/e60eadb4-124e-447f-9f22-04ebf41c1930

A PDF accompanying this announcement is accessible at

http://ml.globenewswire.com/Useful resource/Obtain/22ca4cc0-03ff-43cc-99a4-17ccd78d7ce3

Primary Logo



RELATED ARTICLES

Most Popular

Recent Comments